+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
ID02502162

Study of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome in Adults Aged 18 to 70

Led by Stanford University · Updated on 2025-05-29

120

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating low-dose naltrexone LDN as a potential treatment for symptom relief in people with complex regional pain syndrome CRPS. This study compares LDN with a placebo to understand their effects on pain severity. Participants will be randomly assigned to one of the two groups in this interventional trial. Participants will take either 4.5 mg of naltrexone hydrochloride once daily or a sugar pill as a placebo for several weeks. The study is designed with quadruple masking to ensure unbiased results. Participants will attend study visits either in person or virtually and complete questionnaires during the treatment period. Throughout the study, participants will be monitored for changes in their pain severity, with primary outcomes measured approximately four weeks after the treatment ends. The study involves questionnaires and follow-up visits to assess symptom changes. The entire process is overseen by Stanford University, and participants will be involved until the study concludes in July 2027.

CONDITIONS

Brief Title

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Research Team

B

Birute Gedrimaite

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here